Dupilumab in COPD Linked to Lower Mortality, Better Long-Term …
November 6, 2024. Dupilumab in COPD was linked to lower risk for all-cause mortality (HR, 0.53), emergency visits (HR, 0.78), exacerbations (HR, 0.59), and pneumonia (HR, 0.65). Dupilumab was associated with a decreased risk for all-cause mortality, emergency visits, acute exacerbations (AEs), respiratory failure, and respiratory infections in ...
Second Phase 3 clinical trial again shows dupilumab lessens …
May 20, 2024 · Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal...
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 ...
May 20, 2024 · Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation, has shown efficacy...
Dupilumab in Line to Be the First Approved COPD Biologic
Dec 28, 2023 · While biologic agents for asthma have been approved for 2 decades, none are currently approved for chronic obstructive pulmonary disease (COPD) -- but dupilumab (Dupixent) is expected to be the...
Nov 27, 2023 · The second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant
Sep 11, 2024 · The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of...
Dupilumab for COPD with Type 2 Inflammation Indicated ...
May 21, 2023 · Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. Methods.
Dupixent® (dupilumab) Late-Breaking Data from NOTUS ...
May 20, 2024 · Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 …
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
Dupilumab Reduces COPD Exacerbations in Second Phase 3 Trial
Nov 27, 2023 · Dupixent ® (dupilumab) significantly reduced COPD exacerbations in second positive phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this...
- Some results have been removed